Chiusura precedente | 0,1000 |
Aperto | 0,1000 |
Denaro | 0,0000 |
Domanda | 0,6500 |
Prezzo d'esercizio | 2,50 |
Scadenza | 2024-07-19 |
Min-Max giorno | 0,1000 - 0,1000 |
Contratto - Min-Max | N/D |
Volume | |
Open Interest | 240 |
CANTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2023 financial results will be reported after the market closes on Thursday, November 9th. Management will host a conference call at 5:00 p.m. Eastern Time on Novemb
Thanks Stakeholders who Advocated for PatientsCANTON, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds today’s decision by the three Medicare Administrative Contractors (MACs) to withdraw the final local coverage determinations (LCDs) for Skin Substitute Graft
CANTON, Mass. , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that company management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from Septemb